Volume 4 Supplement 1

Nasal-Ocular Reflexes and Their Role in the Management of Allergic Rhinoconjunctivitis With Intranasal Steroids

Open Access

Nasal-Ocular Reflexes and Their Role in the Management of Allergic Rhinoconjunctivitis With Intranasal Steroids

World Allergy Organization Journal20114:249

DOI: 10.1186/1939-4551-4-S1-S1

Published: 15 January 2011

Abstract

Allergic rhinitis is a common disorder and involves the reaction to environmental allergens with resultant nasal and eye symptoms. The pathophysiologic mechanisms of the eye symptoms in allergic conjunctivitis include a direct effect on the eye by deposited allergen and indirect effects related to the deposition of allergen in the nasal mucosa. One of these proposed mechanisms is the existence of a nasal-ocular reflex whereby the nasal allergic reaction leads to an afferent reflex response, the efferent limb of which results in eye symptoms. Among the treatments available for allergic rhinitis, intranasal steroids are most efficacious for nasal symptoms and have also shown sizeable efficacy related to eye symptoms. We speculated that the effect of intranasal steroids on eye symptoms in allergic rhinitis was related to their inhibition of the nasal-ocular reflex and present data previously generated from our laboratory to support this assumption in a nasal challenge model.

Keywords

Nasal-ocular reflex allergic rhinoconjuctivitis nasal challenge intranasal steroids

Allergic rhinitis is characterized by an IgE-mediated reaction to environmental allergens. It is a common disorder affecting up to 40 million Americans with adult prevalence estimates ranging from 10 to 30% and pediatric prevalence estimates as high as 40% rendering it the most common chronic condition in children.1 Several reports also support substantial increases in the prevalence of allergic rhinoconjunctivitis (AR) in developed countries in recent decades making it an important health problem[13].

Although often referred to as allergic rhinitis, this disease actually involves eye symptoms in addition to the nasal symptoms, hence the more appropriate term, AR. In fact, recent epidemiologic data has shown that ocular symptoms, defined as 'episodes of watery, itchy eyes,' affected 40% of the adult population of the United States during a 12-month period[4]. Another study showed that the incidence of conjunctivitis was high (~88%) in patients experiencing allergic rhinitis during the cypress pollen season[5]. Ocular symptoms are not only common, but also distressing for allergy sufferers, with more than 50% stating that watery and red/itchy eyes were moderately to extremely bothersome in the Allergies in America survey[6]. Furthermore, in 15% of sufferers, the ocular component of the allergic hypersensitivity reaction was the most bothersome symptom[6].

In addition to the typical nasal and eye symptoms, AR leads to a significant impairment of the quality of life of its sufferers when measured by both generic and specific quality of life instruments[7, 8]. Also associated with the disease are fatigue and daytime sleepiness,[7, 9] reduced work productivity,[1012] impaired cognitive functioning,[13, 14] reduced learning abilities,[15] and impaired sleep[16].

The high prevalence of this benign, but chronic, condition, its adverse effects on quality of life, work performance, and productivity on the job, and the treatments sought by the sufferers to alleviate the symptoms all result in significant health care expenditure. The healthcare costs related to AR have been reported to be US$5.9 billion annually in the United States, with medication use accounting for 25% of these costs[17].

Pathophysiology Of AR

The pathophysiologic mechanisms involved in AR start by the sensitization of the nasal mucosa to a certain allergen that involves multiple interactions among antigen presenting cells, T lymphocytes, and B cells and lead to the production of antigen-specific IgE antibodies, which then localize to mast cells and basophils. Subsequent exposure leads to crosslinking of specific IgE receptors on mast cells and their resultant degranulation, with the release of a host of inflammatory mediators that are, in large part, responsible for allergic nasal symptoms that include sneezing, rhinorrhea, itching, and nasal congestion. Other proinflammatory sub-stances are also generated after antigen exposure, most prominent are eosinophil products and cytokines. Cytokines are thought to be generated in part by lymphocytes, which are abundant in resting and stimulated nasal mucosa, and also by mast cells that have an important role in the storage and production and secretion of cytokines. Cytokines will up-regulate adhesion molecules on the vascular endothelium, and possibly on marginating leukocytes, and lead to the migration of these inflammatory cells into the site of tissue inflammation. Various cytokines will also promote the chemotaxis and survival of these recruited inflammatory cells and lead to a secondary immune response by virtue of their capability to promote IgE synthesis by B cells. Also important is the nervous system, which amplifies the allergic reaction by central and peripheral reflexes that result in changes at sites distant from those of antigen deposition such as the eye, sinuses and lower airway. These inflammatory changes lower the threshold of mucosal responsiveness to various specific and nonspecific stimuli, making allergic patients more responsive to stimuli to which they are exposed every day.

The pathophysiologic mechanisms thought to be involved in the generation of ocular symptoms in patients with AR deserve special attention. It is likely that these symptoms result both from the direct effects of allergen deposition on the conjunctiva but also because of nasal ocular reflexes. In support of direct allergen deposition resulting in the symptoms is the fact that ocular allergen challenge leads to symptoms of watery and itchy eyes that are associated with the release of inflammatory mediators, including histamine, in ocular secretions[18, 19]. In support of nasal ocular reflexes is the fact that nasonasal reflexes, that is, the generation of symptoms in one nasal cavity in response to stimulation of the other cavity, are well described and have been shown to occur in response to several stimuli including allergen, histamine, cold dry air, and capsaicin[2024]. There is also evidence suggesting that nasal reflexes in response to allergen challenge lead to an inflammatory response in the maxillary sinus[25]. Therefore, it seems plausible that allergen depositing on the nasal mucosa can trigger afferent reflexes which then propagate centrally. The efferent limbs of these reflexes could then be propagated not only to the contralateral nasal cavity but also to both conjunctivae and maxillary sinuses. Another possible mechanism is that the nasal allergic reaction leads to the release of mediators from the nose and up-regulation of circulating cells, which, when attracted to the eye, are primed to release more mediators and cause more severe symptoms. One last possible mechanism of eye symptoms in AR is direct propagation of allergen from the nose to the eye via the nasolacrimal duct. This is not a likely mechanism as the direction of flow of secretions within the nasolacrimal duct is usually from the eye to the nose and not in the opposite direction. Furthermore, the orifice of the nasolacrimal duct in the nasal cavity is in the inferior meatus, well shielded by the inferior turbinate from external penetration by allergen.

Intranasal Steroids

Many therapies are available for the treatment of AR. These include antihistamines (systemic and topical), decongestants (systemic and topical), leukotriene modifiers, anticholinergics, intranasal steroids, and combination therapies. Multiple studies comparing the different agents available for treatment indeed support the superior efficacy of intranasal steroids for allergic rhinitis[26, 27]. As a consequence, the comprehensive role of intranasal steroids is well recognized as evidenced in both European and American guidelines for the treatment of allergic rhinitis[28, 29].

Traditionally, allergic rhinitis clinical trials have focused on nasal symptoms; however, recent studies have highlighted the prevalence and significance of ocular symptoms and thus, the effect of intranasal steroids on ocular symptoms has been the focus of recent investigation. Indeed, studies have shown that intranasal steroids are effective in the control of ocular symptoms almost to the same degree that they positively impact nasal symptoms. In an early placebo-controlled, double blind, trial in subjects with seasonal allergic rhinitis, Settipane and colleagues showed that both total ocular and total nasal symptoms were significantly lowered after treatment with triamcinolone acetonide[30]. More recently, ocular symptoms have been included in many trials and more data has emerged to support the efficacy of intranasal steroids in the control of eye symptoms in allergic rhinitis.

In a retrospective analysis of pooled data from 7 randomized, double-blind trials that compared the efficacy of fluticasone propionate and placebo in seasonal allergic rhinitis in 1645 patients, intranasal fluticasone propionate was found to be significantly more effective than placebo in reducing the total ocular symptom scores after 1 and 2 weeks of treatment[31]. A similar post hoc analysis of the effect of mometasone furoate on ocular symptoms was performed on the results of a placebo controlled clinical trial performed in 353 subjects with seasonal allergic rhinitis[32]. The subjects recorded symptoms of ocular itching, tearing, and redness and these were combined into a total ocular symptom score (TOSS) for analysis. Mometasone furoate treatment resulted in a significant reduction from baseline in TOSS compared with placebo and the greatest improvement with individual symptoms occurred with tearing. Fluticasone furoate, a more recent addition to the intranasal steroid market in the United States, is also more effective than placebo in reducing ocular symptoms associated with seasonal allergic rhinitis. Comparison of once-daily intranasal fluticasone furoate with placebo in subjects with seasonal allergic rhinitis who had moderate-to-severe total ocular symptom scores at baseline concluded that mean reductions from baseline were significantly greater with fluticasone furoate than with placebo for total ocular symptom scores and each of the individual ocular symptoms[33]. Two other published studies support this conclusion[34, 35].

Although the mechanism of action of intranasal steroid sprays in relieving ocular symptoms is not understood, several mechanisms have been proposed. By decreasing nasal inflammation, intranasal steroids may modulate or normalize the excess stimulation of reflex neural activity that occurs during allergic reactions, thereby reducing ocular symptoms. In addition, by inhibiting local nasal inflammation, that is, the production of cytokines and infiltration of inflammatory cells, intranasal steroids may have indirect systemic effects that reduce the recruitment of inflammatory cells in other tissues, including the eyes. This effect would be observed on the late response to ocular challenge with antigen. Some authors have suggested that intranasal steroids increase drainage in inflamed nasolacrimal ducts, thereby reducing conjunctival exposure to allergens and inflammatory mediators. However, duct patency has been found to be maintained in subjects who had symptomatic allergic responses after ocular challenge[36]. It has also been suggested that intranasal steroids might travel through the nasolacrimal duct, exerting their anti-inflammatory effect directly on the conjunctiva. However, the lack of steroid-related side effects such as glaucoma and cataracts[37, 38] after prolonged use suggests that movement of intranasal steroids through the nasolacrimal duct is not a plausible mechanism for the ocular effects of these agents.

The Nasal-Ocular Reflex Mechanism of Rhinoconjunctivitis and the Effect of Intranasal Steroids on the Reflex

To attempt to explain the beneficial effect of intranasal steroids on eye symptoms in AR, we focused on the nasalocular reflex response. Prior studies of the nasal ocular reflex after antigen stimulation have yielded mixed results. Lebel and colleagues, in a nasal-challenge study, reported that ~20% of allergic rhinitis sufferers experienced ocular symptoms during nasal provocation with grass pollen, suggesting that allergic ocular symptoms can occur without direct exposure of the conjunctiva to allergen[39]. Loth and Bende, on the other hand, concluded that nasal challenge with allergen does not increase lacrimal gland secretion, because inhibition of parasympathetic nerves by lidocaine did not reduce tears[40]. The conclusions of their study can be questioned because the placebo arm failed to demonstrate any significant increase in lacrimation after nasal challenge with allergen thus putting the value of the results obtained from the lidocaine arm of the study in doubt. Other studies using different forms of stimulation have supported the existence of a nasal-ocular reflex. Zilstorff-Pedersen reported bilateral lacrimation after unilateral irritation of the nasal mucosa[41]. Using capsaicin as a stimulant and as a desensitizer, Philip and colleagues showed that unilateral nasal challenge with capsaicin produced ocular tearing and watering. This was reduced significantly after repeated capsaicin challenges that led to desensitization of the response[24].

To determine whether nasal challenge with antigen induces a nasal-ocular reflex, we performed a double-blind crossover trial in 20 subjects with seasonal allergic rhinitis[42]. We speculated that histamine, released by mast cells upon allergen deposition on the nasal mucosa, initiated the afferent limb of the reflex response which resulted in contralateral nasal symptoms and also ocular symptoms within minutes of challenge. Therefore, we evaluated the effect of a topical antihistamine, azelastine, applied to the nasal cavity on the side of challenge on both the nasal and ocular reflex responses. Subjects were challenged with antigen in one nostril using filter paper discs, and the response was monitored in both nostrils and in both eyes. Symptoms were recorded. Discs (intranasally) and Schirmer strips (intraocularly) were used for collecting secretions in both nostrils and eyes and were weighed before and after collection allowing us to calculate the weight of generated nasal and ocular secretions, objective measures of rhinorrhea and watery eyes, respectively. The discs and Schirmer strips were then placed in buffer to allow elution of collected secretions and the supernatants were measured for levels of histamine, an indicator of mast cell activation, and albumin, a marker of vascular permeability.

Subjects were treated once topically at the site of challenge with azelastine or placebo. After placebo treatment, ipsilateral nasal challenge caused nasal symptoms and an increase in bilateral nasal secretion weights, both of which were blocked by treatment with azelastine. Levels of histamine and albumin increased only at the site of nasal challenge and azelastine inhibited the increase in albumin, but not that in histamine. These findings are not new and have been demonstrated by our and other laboratories previously. They cement the existence of a nasonasal reflex and the important role of histamine in its generation. As far as the ocular response, symptoms of itchy and watery eyes increased significantly after allergen challenge, compared with sham challenge, when the subjects were premedicated with placebo (Figure 1). This supports our hypothesis of the role of the naso-ocular reflex in the generation of ocular symptoms after allergen deposition on the nasal mucosa. Furthermore, the eye symptoms were inhibited by premedication with azelastine also suggesting that histamine, released by allergen challenge, was important in the genesis of the ocular symptoms (Figure 1). Ocular secretion weights increased bilaterally after placebo and were not inhibited by azelastine. Unfortunately, ocular secretion collection was technically difficult and ocular secretion weights are probably not as reliable an indicator of the ocular response as eye symptoms. This is related to the fact that the Schirmer strips led to irritation of the eyes and a high baseline of secretions even after the sham nasal challenge. In summary, the above data suggested that nasal allergen challenge induces histamine release at the site of the challenge, which causes both a nasonasal and a nasal ocular reflex. This antigen induced reflex is blocked by an H1 receptor antagonist applied at the site of the challenge. These observations support the hypothesis that eye symptoms associated with allergic rhinitis probably arise, at least in part, from a nasal-ocular reflex.
Figure 1

Nasal-ocular reflex and inhibition by pretreatment with azelastine. Watery eye and itchy eye symptom scores after diluent and allergen challenges. There was a significant increase in both itchy and watery eye symptoms after allergen challenge compared with respective diluent challenges with the patients on placebo depicted by the open bars (*P ≤ 0.004 vs respective diluents). Pretreatment with azelastine resulted in a significant reduction in the net change from the diluent response for both itchy (P = 0.02) and watery eye (P = 0.03) symptoms. (From Naclerio RM, Pinto J, deTineo M, Baroody FM. Elucidating the mechanism underlying the ocular symptoms associated with allergic rhinitis. Allergy Asthma Proc. 2008;29:24-28.)

To follow up on this study and investigate the effects of intranasal steroids on the nasal-ocular reflex, we performed double-blind, placebo-controlled, cross-over experiment in 20 subjects who had seasonal allergic rhinitis[43]. We hypothesized that repeated nasal allergen challenges would lead to priming and augmentation of nasonasal and nasal-ocular reflexes and that intranasal steroids would decrease inflammation and subsequently inhibit both nasonasal and nasalocular reflexes thus resulting in reduction of eye symptoms. Nasal antigen challenge was performed consecutively for 3 days after 1 week of treatment with either placebo or fluticasone furoate nasal spray. Subjects recorded their nasal and ocular symptoms, and nasal secretions were quantified. Nasal scrapings for quantifying eosinophils were obtained before each antigen challenge. When subjects were receiving placebo, nasal challenge with antigen led to sneezing, a nasonasal and a nasal-ocular reflex. Priming in the number of sneezes, contralateral nasal secretion weights, and total eye symptoms were observed (Figure 2). Pretreatment with fluticasone furoate nasal spray reduced sneezing, the nasonasal and nasal-ocular reflexes, and the amount of eosinophils in nasal secretions (Figure 2). The results of this study helped confirm the existence of a nasal-ocular reflex after allergen challenge of the nose, and demonstrated the exaggeration, or priming, of this reflex by repeated exposure to allergen and thus supported the role of the nasal-ocular reflex in the genesis of at least part of the eye symptoms in patients with AR. This study also helped demonstrate the efficacy of an intranasal steroid (fluticasone furoate) in reducing allergic inflammation, priming and subsequently the nasal-ocular reflex and ocular symptoms. Our results therefore support a mechanism that helps explain how control of eye symptoms can be achieved by the administration of an intranasal steroid in patients with seasonal allergic rhinitis.
Figure 2

Effect of fluticasone furoate nasal spray on total eye symptoms after allergen challenge. The x-axis shows the days of consecutive challenge. Placebo responses are depicted in the open bars and fluticasone furoate (FF) in the solid bars. Net change from diluent is depicted as mean ± SEM (n = 20). †P ≤ 0.04 versus day 1 on placebo treatment illustrating priming and *P < 0.01 versus placebo demonstrating the inhibitory effect of active treatment with FF.

Conclusion

Eye symptoms (itching, watery eyes, and redness) are an important part of the overall burden of AR and are associated with significant bother to allergy sufferers. These effects probably occur by several mechanisms, the most obvious of which, is the direct deposition of allergen in the conjunctiva and the generation of an ocular inflammatory response. Another mechanism that might contribute to the genesis of ocular symptoms in allergic individuals is a neural reflex generated in the nose upon exposure to allergen that results in an amplification of the allergic response to the other nostril and also to both eyes. This mechanism might explain the efficacy of intranasally administered steroids in controlling ocular symptoms. In this article, we have reviewed evidence obtained both from experimental challenges and clinical studies that supports an important role for the nasalocular reflex in the eye symptoms of AR and, at least partially, explains the efficacy of intranasal steroids in controlling these symptoms.

Declarations

Acknowledgements

The contents of the present manuscript were presented as an invited World Allergy Organization Lecture at the First Middle East Asia Allergy Asthma and Immunology Congress (MEAAAIC) in Dubai, UAE, March 26-29, 2009.

Authors’ Affiliations

(1)
Department of Surgery, Section of Otolaryngology-Head and Neck Surgery, The University of Chicago Medical Center

References

  1. US Dept of Health and Human Services. Evid Rep Technol Assess. 2002, 54: 1-198. AHRQ Pub No 02-E024Google Scholar
  2. Linneberg A, Nielsen NH, Madsen F, Frølund L, Dirksen A, Jørgensen T: Increasing prevalence of specific IgE to aeroallergens in an adult population: two cross-sectional surveys 8 years apart: the Copenhagen Allergy Study. J Allergy Clin Immunol. 2000, 106: 247-252. 10.1067/mai.2000.108312.View ArticlePubMedGoogle Scholar
  3. Sibbald B, Rink E, D'Souza M: Is the prevalence of atopy increasing?. Br J Gen Pract. 1990, 40: 338-340.PubMedPubMed CentralGoogle Scholar
  4. Singh K, Bielory L, Hackensack NJ, et al: Epidemiology of ocular allergy symptoms in United States adults (1988-1994). ACAAI. 2006, 34: (Abstract)Google Scholar
  5. Bousquet J, Knani J, Hejjaoui A, Ferrando R, Cour P, Dhivert H, Michel FB: Heterogeneity of atopy. I. Clinical and immunologic characteristics of patients allergic to cypress pollen. Allergy. 1993, 48: 183-188. 10.1111/j.1398-9995.1993.tb00711.x.View ArticlePubMedGoogle Scholar
  6. HealthSTAR Communications: Allergies in America: executive summary. [http://www.myallergiesinamerica.com]
  7. Stuck BA, Czajkowski J, Hagner AE, Klimek L, Verse T, Hörmann K, Maurer JT: Changes in daytime sleepiness, quality of life, and objective sleep patterns in seasonal allergic rhinitis: a controlled clinical trial. J Allergy Clin Immunol. 2004, 113: 663-668. 10.1016/j.jaci.2003.12.589.View ArticlePubMedGoogle Scholar
  8. Juniper EF: Impact of upper respiratory allergic diseases on quality of life. J Allergy Clin Immunol. 1998, 101: S386-S391. 10.1016/S0091-6749(98)70227-1.View ArticlePubMedGoogle Scholar
  9. Marshall PS, O'Hara C, Steinberg P: Effects of seasonal allergic rhinitis on fatigue levels and mood. Psychosom Med. 2002, 64: 684-691. 10.1097/01.PSY.0000021944.35402.44.PubMedGoogle Scholar
  10. Bousquet J, Neukirch F, Bousquet PJ, Gehano P, Klossek JM, Le Gal M, Allaf B: Severity and impairment of allergic rhinitis in patients consulting in primary care. J Allergy Clin Immunol. 2006, 117: 158-162. 10.1016/j.jaci.2005.09.047.View ArticlePubMedGoogle Scholar
  11. Tanner LA, Reilly M, Meltzer EO, Bradford JE, Mason J: Effect of fexofenadine hydrochloride on quality of life and work, classroom, and daily activity impairment in patients with seasonal allergic rhinitis. Am J Managed Care. 1999, 5 (Suppl): S235-S247.Google Scholar
  12. Blanc PD, Trupin L, Eisner M, Earnest G, Katz PP, Israel L, Yelin EH: The work impact of asthma and rhinitis: findings from a populationbased survey. J Clin Epidemiol. 2001, 54: 610-618. 10.1016/S0895-4356(00)00349-8.View ArticlePubMedGoogle Scholar
  13. Wilken JA, Berkowitz R, Kane R: Decrements in vigilance and cognitive functioning associated with ragweed-induced allergic rhinitis. Ann Allergy Asthma Immunol. 2002, 89: 372-380. 10.1016/S1081-1206(10)62038-8.View ArticlePubMedGoogle Scholar
  14. Marshall PS, O'Hara C, Steinberg P: Effects of seasonal allergic rhinitis on selective cognitive abilities. Ann Allergy Asthma Immunol. 2000, 84: 371-373. 10.1016/S1081-1206(10)62266-1.View ArticleGoogle Scholar
  15. Vuurman EF, van Veggel LM, Uiterwijk MM, Leutner D, O'Hanlon JF: Seasonal allergic rhinitis and antihistamine effects on children's learning. Ann Allergy. 1993, 71: 121-126.PubMedGoogle Scholar
  16. Léger D, Annesi-Maesano I, Carat F, Rugina M, Chanal I, et al: Allergic rhinitis and its consequences on quality of sleep: an unexplored area. Arch Intern Med. 2006, 166: 1744-1748. 10.1001/archinte.166.16.1744.View ArticlePubMedGoogle Scholar
  17. Ray NF, Baraniuk JN, Thamer M, Rinehart CS, Gergen PJ, et al: Direct expenditures for the treatment of allergic rhinoconjunctivitis in 1996, including the contributions of related airway illnesses. J Allergy Clin Immunol. 1999, 103 (Pt 1): 401-407.View ArticlePubMedGoogle Scholar
  18. Bielory L: Update on ocular allergy treatment. Expert Opin Pharmacother. 2002, 3: 541-553. 10.1517/14656566.3.5.541.View ArticlePubMedGoogle Scholar
  19. McGill JI, Holgate ST, Church MK, Anderson DF, Bacon A: Allergic eye disease mechanisms. Br J Ophthalmol. 1998, 82: 1203-1214. 10.1136/bjo.82.10.1203.View ArticlePubMedPubMed CentralGoogle Scholar
  20. Baroody FM, Ford S, Lichtenstein LM, Kagey-Sobotka A, Naclerio RM: Physiologic responses and histamine release after nasal antigen challenge: effect of atropine. Am J Respir Crit Care Med. 1994, 149: 1457-1465. 10.1164/ajrccm.149.6.7516250.View ArticlePubMedGoogle Scholar
  21. Wagenmann M, Baroody FM, Kagey-Sobotka A, Lichtenstein LM, Naclerio RM: The effect of terfenadine on unilateral nasal challenge with allergen. J Allergy Clin Immunol. 1994, 93: 594-605. 10.1016/S0091-6749(94)70071-0.View ArticlePubMedGoogle Scholar
  22. Baroody FM, Wagenmann M, Naclerio RM: A comparison of the secretory response of the nasal mucosa to histamine and methacholine. J Appl Physiol. 1993, 74: 2661-2671.PubMedGoogle Scholar
  23. Philip G, Jankowski R, Baroody F, Naclerio RM, Togias AG: Reflex activation of nasal secretion by unilateral inhalation of cold dry air. Am Rev Respir Dis. 1993, 148: 1616-1622. 10.1164/ajrccm/148.6_Pt_1.1616.View ArticlePubMedGoogle Scholar
  24. Philip G, Baroody FM, Proud D, Naclerio RM, Togias AG: The human nasal response to capsaicin. J Allergy Clin Immunol. 1994, 94: 1035-1045. 10.1016/0091-6749(94)90122-8.View ArticlePubMedGoogle Scholar
  25. Baroody FM, Mucha SM, deTineo M, Naclerio RM: Nasal challenge with allergen leads to maxillary sinus inflammation. J Allergy Clin Immunol. 2008, 121: 1126-1132. 10.1016/j.jaci.2008.02.010.View ArticlePubMedGoogle Scholar
  26. Wilson AM, O'Byrne PM, Parameswaran K: Leukotriene receptor antagonists for allergic rhinitis: a systematic review and meta-analysis. Am J Med. 2004, 116: 338-344. 10.1016/j.amjmed.2003.10.030.View ArticlePubMedGoogle Scholar
  27. Weiner JM, Abramson MJ, Puy RM: Intranasal corticosteroids versus oral H1 receptor antagonists in allergic rhinitis: systematic review of randomised controlled trials. BMJ. 1998, 317: 1624-1629. 10.1136/bmj.317.7173.1624.View ArticlePubMedPubMed CentralGoogle Scholar
  28. Wallace DV, Dykewicz MS, Bernstein DI, Blessing-Moore J, Cox L, et al: The diagnosis and management of rhinitis: an updated practice parameter. J Allergy Clin Immunol. 2008, 122: S1-S84. 10.1016/j.jaci.2008.06.003.View ArticlePubMedGoogle Scholar
  29. Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, et al: Allergic rhinitis and its impact on asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy. 2008, 63 (Suppl 86): 8-160.View ArticlePubMedGoogle Scholar
  30. Settipane G, Korenblat PE, Winder J, Lumry W, Murphree J, Alderfer VB, Simpson B, Smith JA: Triamcinolone acetonide aqueous nasal spray in patients with seasonal ragweed allergic rhinitis: a placebo-controlled, double-blind study. Clin Ther. 1995, 17: 252-263. 10.1016/0149-2918(95)80023-9.View ArticlePubMedGoogle Scholar
  31. DeWester J, Philpot EE, Westlund RE, Cook CK, Rickard KA: The efficacy of intranasal fluticasone propionate in the relief of ocular symptoms associated with seasonal allergic rhinitis. Allergy Asthma Proc. 2003, 24: 331-337.PubMedGoogle Scholar
  32. Anolik R, Nathan RA, Schenkel E, Danzig MR, Gates D, Varghese S: Intranasal mometasone furoate alleviates the ocular symptoms associated with seasonal allergic rhinitis: results of a post hoc analysis. Int Arch Allergy Immunol. 2008, 147: 323-330. 10.1159/000144040.View ArticlePubMedGoogle Scholar
  33. Kaiser HB, Naclerio RM, Given J, Toler TN, Ellsworth A, Philpot EE: Fluticasone furoate nasal spray: a single treatment option for the symptoms of seasonal allergic rhinitis. J Allergy Clin Immunol. 2007, 119: 1430-1437. 10.1016/j.jaci.2007.02.022.View ArticlePubMedGoogle Scholar
  34. Martin BG, Ratner PH, Hampel FC, Andrews CP, Toler T, et al: Optimal dose selection of fluticasone furoate nasal spray for treatment of seasonal allergic rhinitis in adults and adolescents. Allergy Asthma Proc. 2007, 28: 216-225. 10.2500/aap.2007.28.2983.View ArticlePubMedGoogle Scholar
  35. Fokkens WJ, Jogi R, Reinartz S, Sidorenko I, Sitkauskiene B, et al: Once daily fluticasone furoate nasal spray is effective in seasonal allergic rhinitis caused by grass pollen. Allergy. 2007, 62: 1078-1084. 10.1111/j.1398-9995.2007.01522.x.View ArticlePubMedGoogle Scholar
  36. Spangler DL, Abelson MB, Ober A, Gotnes PJ: Randomized, doublemasked comparison of olopatadine ophthalmic solution, mometasone furoate monohydrate nasal spray, and fexofenadine hydrochloride tablets using the conjunctival and nasal allergen challenge models. Clin Ther. 2003, 25: 2245-2267. 10.1016/S0149-2918(03)80217-5.View ArticlePubMedGoogle Scholar
  37. Howland WC: Fluticasone propionate: topical or systemic effects?. Clin Exp Allergy. 1996, 26 (Suppl 3): 18-22.View ArticlePubMedGoogle Scholar
  38. Derby L, Maier WC: Risk of cataract among users of intranasal corticosteroids. J Allergy Clin Immunol. 2000, 105: 912-916. 10.1067/mai.2000.106044.View ArticlePubMedGoogle Scholar
  39. Lebel B, Bousquet J, Morel A, Chanal I, Godard P, Michel FB: Correlation between symptoms and the threshold for release of mediators in nasal secretions during nasal challenge with grass-pollen grains. J Allergy Clin Immunol. 1988, 82: 869-877. 10.1016/0091-6749(88)90092-9.View ArticlePubMedGoogle Scholar
  40. Loth S, Bende M: Effect of nasal anaesthesia on lacrimal function after nasal allergen challenge. Clin Exp Allergy. 1994, 24: 375-376. 10.1111/j.1365-2222.1994.tb00249.x.View ArticlePubMedGoogle Scholar
  41. Zilstorff-Pedersen K: Quantitative measurements of the nasolacrimal reflex. Arch Otolaryngol Head Neck Surg. 1965, 81: 457-462. 10.1001/archotol.1965.00750050470003.View ArticleGoogle Scholar
  42. Baroody FM, Foster KA, Markaryan A, deTineo M, Naclerio RM: Nasal-ocular reflexes contribute to eye symptoms in patients with allergic rhinitis. Ann Allergy Asthma Immunol. 2008, 100: 194-199. 10.1016/S1081-1206(10)60442-5.View ArticlePubMedGoogle Scholar
  43. Baroody FM, Shenaq D, DeTineo M, Wang J, Naclerio RM: Fluticasone furoate nasal spray reduces the nasal ocular reflex: a mechanism for the efficacy of topical steroids in controlling allergic eye symptoms. J Allergy Clin Immunol. 2009, 123: 1342-1348. 10.1016/j.jaci.2009.03.015.View ArticlePubMedGoogle Scholar
  44. Naclerio RM, Pinto J, deTineo M, Baroody FM: Elucidating the mechanism underlying the ocular symptoms associated with allergic rhinitis. Allergy Asthma Proc. 2008, 29: 24-28. 10.2500/aap2008.29.3075.View ArticlePubMedGoogle Scholar

Copyright

© World Allergy Organization; licensee BioMed Central Ltd. 2011

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.